### 1 A randomized controlled trial of antibody response to 2019-20 cell-based

- 2 inactivated and egg-based live attenuated influenza vaccines in children and
   3 young adults
- 4
- 5 Authors: Katherine V. Williams<sup>a,\*</sup>, Bo Zhai<sup>b</sup>, John F. Alcorn<sup>b,c</sup>, Mary Patricia Nowalk<sup>a</sup>,
- 6 Min Z. Levine<sup>d</sup>, Sara S. Kim<sup>d</sup>, Brendan Flannery<sup>d</sup>, Krissy Moehling Geffel<sup>a</sup>, Amanda
- 7 Jaber Merranko<sup>e</sup>, Jennifer P. Nagg<sup>c</sup>, Mark Collins<sup>a</sup>, Michael Susick<sup>a</sup>, Karen S. Clarke<sup>a</sup>,
- 8 Richard K. Zimmerman<sup>a</sup>, Judith M. Martin<sup>c</sup>
- 9
- <sup>10</sup> <sup>a</sup>Department of Family Medicine, University of Pittsburgh,
- 11 4420 Bayard Street, Suite 520, Pittsburgh, PA 15260, USA
- <sup>12</sup> <sup>b</sup>Department of Immunology, University of Pittsburgh,
- 13 9127 Rangos Research Center, 4401 Penn Avenue, Pittsburgh, PA 15224 USA
- <sup>14</sup> <sup>c</sup>Department of Pediatrics, University of Pittsburgh,
- 15 3520 Fifth Avenue, Pittsburgh, PA 15213, USA
- <sup>16</sup> <sup>d</sup>National Center Immunizations and Respiratory Disease,
- 17 Center for Disease Control and Prevention, Atlanta, GA, USA
- <sup>18</sup> <sup>e</sup>Falk Pharmacy, University of Pittsburgh Medical Center (UPMC),
- 19 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
- 20

### 21 Abstract

Background: Hemagglutination inhibition (HAI) titers to the live-attenuated
 influenza vaccine (LAIV4) are typically lower than its counterpart egg-based
 inactivated influenza vaccines (IIV). Similar comparisons have not been made
 between LAIV4 and the 4-strain, cell-culture inactivated influenza vaccine (ccIIV4).
 We compared healthy children and young adult HAI titers against the 2019-2020
 LAIV4 and ccIIV4.

Methods: Participants aged 4-21 years were randomized 1:1 to receive ccIIV4 (n =100) or LAIV4 (n=98). Blood was drawn prevaccination and on day 28 (21-35) post vaccination. HAI assays against egg-grown A/H1N1, A/H3N2, both vaccine B strains and cell-grown A/H3N2 antigens were conducted. Outcomes were geometric mean titers (GMT) and geometric mean fold rise (GMFR) in titers.

33 Results. GMTs to A/H1N1, A/H3N2 and B/Victoria increased following both 34 ccIIV and LAIV and to B/Yamagata following ccIIV (p<0.05). The GMFR range was 2.4-3.0 times higher for ccIIV4 than for LAIV4 (p<0.001). Within vaccine types, egg-35 36 grown A/H3N2 GMTs were higher (p<0.05) than cell-grown GMTs [ccIIV4 day 28: egg=205 (95% CI: 178-237); cell=136 (95% CI:113-165); LAIV4 day 28: egg=96 37 38 (95% CI: 83-112); cell=63 (95% CI: 58-74)]. The GMFR to A/H3N2 cell-grown and 39 egg-grown antigens were similar. Pre-vaccination titers inversely predicted GMFR. 40 *Conclusion:* The HAI response to ccIIV4 was greater than LAIV4 in this study of mostly older children, and day 0 HAI titers inversely predicted GMFR for both 41 42 vaccines. For both vaccines, the A/H3N2 cell-grown antigen levels were lower than 43 egg-grown, but the GMFR for cell-grown and egg-grown did not differ significantly 44 within vaccine type.

- 46 \*Corresponding author: Department of Pediatrics, General Academic Pediatrics,
- 47 3520 Fifth Ave., Pittsburgh, PA, USA. judy.martin@chp.edu (JM Martin)
- 48 Additional author emails: KVW <u>williamskv@upmc.edu</u>; BZ <u>bo.zhai@chp.edu</u>; JFA
- 49 John.Alcorn@chp.edu; MPN tnowalk@pitt.edu; MZL mwl2@cdc.gov; SSK:
- 50 <u>omy1@cdc.gov;</u> BF <u>bif4@cdc.gov;</u> KMG <u>kkm17@pitt.edu;</u> AJM jabera@upmc.edu;
- 51 JPN Jennifer.Nagg@chp.edu; MC mjc@pitt.edu; MS susickm@upmc.edu; KSC
- 52 KAC373@pitt.edu; RKZ zimmrk@upmc.edu.
- 53 Key words: influenza, influenza vaccine, hemagglutination inhibition assay, cell-
- 54 culture-based inactivated influenza vaccine, egg-based live attenuated influenza
- 55 vaccine, randomized controlled trial
- 56 Clinical Trials No.: NCT03982069
- 57 Abbreviations:
- 58 HAI hemagglutination inhibition assay
- 59 IIV inactivated influenza vaccine
- 60 ccIIV4 cell-culture-based inactivated influenza vaccine quadrivalent
- 61 LAIV4 Egg-based live attenuated influenza vaccine quadrivalent
- 62 EMR Electronic medical record
- 63 RDE Receptor-destroying enzyme
- 64 PBS Phosphate-buffered saline
- 65 CDC Centers for Disease Control and Prevention
- 66 FDA Food and Drug Administration
- 67 GMT Geometric mean titers
- 68 GMFR Geometric mean fold rise
- 69 ACIP Advisory Committee on Immunization Practice
- 70 PA-SIIS Pennsylvania Statewide Immunization Information System

#### 71 Abstract

Background: Hemagglutination inhibition (HAI) titers to the live-attenuated
influenza vaccine (LAIV4) are typically lower than its counterpart egg-based
inactivated influenza vaccines (IIV). Similar comparisons have not been made
between LAIV4 and the 4-strain, cell-culture inactivated influenza vaccine (ccIIV4).
We compared healthy children and young adult HAI titers against the 2019-2020
LAIV4 and ccIIV4.

78 Methods: Participants aged 4-21 years were randomized 1:1 to receive 79 ccIIV4 (n =100) or LAIV4 (n=98). Blood was drawn prevaccination and on day 28 80 (21-35) post vaccination. HAI assays against egg-grown A/H1N1, A/H3N2, both 81 vaccine B strains and cell-grown A/H3N2 antigens were conducted. Outcomes were 82 geometric mean titers (GMT) and geometric mean fold rise (GMFR) in titers. 83 Results. GMTs to A/H1N1, A/H3N2 and B/Victoria increased following both 84 ccIIV and LAIV and to B/Yamagata following ccIIV (p<0.05). The GMFR range was 85 2.4-3.0 times higher for ccIIV4 than for LAIV4 (p<0.001). Within vaccine types, egg-86 grown A/H3N2 GMTs were higher (p<0.05) than cell-grown GMTs [ccIIV4 day 28: 87 egg=205 (95% CI: 178-237); cell=136 (95% CI:113-165); LAIV4 day 28: egg=96 88 (95% CI: 83-112); cell=63 (95% CI: 58-74)]. The GMFR to A/H3N2 cell-grown and 89 egg-grown antigens were similar. Pre-vaccination titers inversely predicted GMFR. 90 *Conclusion:* The HAI response to ccIIV4 was greater than LAIV4 in this study 91 of mostly older children, and day 0 HAI titers inversely predicted GMFR for both 92 vaccines. For both vaccines, the A/H3N2 cell-grown antigen levels were lower than 93 egg-grown, but the GMFR for cell-grown and egg-grown did not differ significantly 94 within vaccine type.

95

# 96 **1. Introduction**

97	Influenza is a major public health burden causing millions of illnesses and
98	outpatient visits and resulting in tens of thousands of hospitalizations and deaths in
99	the U.S. annually [1]. Vaccination is the primary influenza prevention method.
100	Advances in vaccine technology have resulted in multiple vaccine types licensed for
101	use in the U.S., comprising intramuscularly administered inactivated influenza
102	vaccines (IIV), including a quadrivalent cell culture-based inactivated vaccine
103	(ccIIV4), and nasally administered, egg-based live attenuated influenza vaccine
104	(LAIV4). The Advisory Committee on Immunization Practice (ACIP), which sets
105	civilian immunization policy for the United States, recommends vaccination with any
106	licensed vaccine, without preference [2].
107	Several factors can affect the immune response to either vaccine type,
108	including pre-existing antibodies, prior vaccination status, and age [3-5]. Nasally
109	administered LAIV4, which is absorbed through the nasal mucosa, generates an
110	immune response that differs from direct systemic exposure from intramuscularly
111	administered IIV [6]. Moreover, the manufacturing process may have an impact on
112	immune response. For example, the viruses used for vaccine antigens can be
113	grown in mammalian cell culture or embryonated chicken eggs. Growth in cell
114	culture has the advantage of limiting the virus mutations that often occur during the
115	egg-based manufacturing process. While, egg-based LAIV4 has been shown to be
116	more effective against antigenically different or drifted strains [7], egg-induced
117	mutations in influenza A(H3N2) vaccine viruses have resulted in reduced efficacy of
118	egg-based vaccines [8].
119	Previous research comparing the hemagglutination inhibition (HAI) antibody

120 responses of IIV and LAIV4 has historically demonstrated lower HAI titers in

121	response to LAIV compared to egg-based IIV [3, 6, 9, 10]. These studies were
122	conducted before the reformulation of LAIV4 necessitated by poor vaccine
123	effectiveness [11]. In a previous study among children, we found no differences in
124	seroconversion in children receiving egg- or cell-grown IIV in 2018-19 [12]. The cell-
125	grown IIV4 used in that study contained A/H1N1 that was derived from an egg-based
126	seed leading to a 3:1 cell to egg formulation. The 2019-20 season is the first in
127	which the ccIIV4 formulation is exclusively cell-based. Furthermore, the current
128	LAIV4 has been reformulated to avoid the egg-induced mutations to the A/H3N2
129	antigen. Thus, a comparison of the HAI response to egg- and cell-based antigens
130	for each vaccine in a clinical setting of children and young adults is warranted.
131	The purpose of this randomized controlled trial was to quantify and compare pre-
132	and post vaccination HAI responses to 2019-20 LAIV4 and ccIIV4, among a racially
133	diverse group of children and young adults during the 2019-20 influenza season.
134	

#### 135 **2. Methods**

The Institutional Review Boards at the University of Pittsburgh and the Centers for Disease Control and Prevention (CDC) approved this study. Written informed consent and assent, where appropriate, were obtained from all participants and/or their parents/legal guardians prior to beginning study procedures.

140 2.1 Study Design and Participants

141This study was a randomized controlled clinical trial comparing the serologic142antibody response to two quadrivalent 2019-20 influenza vaccines: cclIV4 (Seqirus143Flucelvax®, lot 261199, 261203) administered intramuscularly in the upper arm144deltoid muscle with a 25-gauge 1 inch needle and egg-based LAIV4 (AstraZeneca145FluMist®, lot LJ2514) administered intranasally with one metered spray in each146nostril.147Healthy participants included patients ages 4-17 years who receive primary

148 care at pediatric and family medicine clinics. These children typically receive annual 149 IV [13] and thus tend to have higher pre-vaccination HAI titers. Other participants up 150 to age 21 who were unvaccinated in the prior season (2018-19) and thus would be 151 expected to have lower pre-vaccination HAI titers, also participated. Participants 152 were recruited and enrolled from September 20, 2019 through November 13, 2019 through: 1) mailings to past research participants; 2) personal approach by research 153 154 assistants/nurses at well-child visits at five primary care health centers (one pediatric 155 and four family medicine practices); and 3) targeted emails to 18-21-year-olds 156 enrolled in an institutional participant-centered research registry. Recruitment ended 157 when the targeted number for enrollment goal was achieved. All study vaccinations 158 were completed by November 25, 2019, prior to regional circulation of influenza 159 virus; the final participant visit was completed on December 18, 2019. Verification of

#### 160 prior year vaccination status was confirmed through the Pennsylvania Statewide

161 Immunization Information System (PA-SIIS) vaccine registry.

162 Eligibility criteria included parental consent for randomization to receive one of 163 the two 2019-20 FDA approved influenza vaccines used in the study. Exclusion 164 criteria included: weight <16.8 kg (37 lb.); known to be pregnant; an 165 immunosuppressing health condition or taking immunosuppressant medications; 166 having already received the 2019-20 influenza vaccine; not able to complete all 167 study visits in the appropriate time window; contraindications to LAIV4 (asthma with 168 treatment for wheezing in the past year, individuals who may have contact with 169 severely immunosuppressed persons) or conditions with precautions to LAIV4 170 vaccine (disorders of the cardiovascular system, seizures, diabetes mellitus, renal or 171 hepatic disease) or severe allergies to eggs or influenza vaccine components. 172 Following screening and consent, a blood sample was drawn. Participants 173 were then randomized to receive one of the two study vaccines in an unblinded 174 manner. In order to ensure that roughly the same number of each vaccine types 175 were administered at each of the enrollment sites, participants were randomized in 176 blocks of four. Sequentially numbered vaccine assignment cards were computer 177 generated based on 1:1 randomization for each vaccine type. The next available 178 numbered card was used to instruct the clinical staff which vaccine to administer 179 under standard vaccination protocols. While the participant and research team were 180 not blinded to randomization allocation, the laboratory team was unaware of 181 participants' group assignment.

182 2.2 Demographic data collection

Baseline data were collected with entry into REDCap<sup>™</sup>, a secure, online
database management system. Baseline demographics included age, and self-

identified: sex, race, ethnicity, parental educational status, and health insurancecoverage.

187 2.3 Hemagglutination inhibition assay

188 Whole blood samples were obtained on participants pre-vaccination and 28 189 days (range 21-35 days) post influenza vaccination in BD Vacutainer<sup>™</sup> serum 190 separator tubes with polymer gel/silica activator additive (BD 367989). Tubes were 191 held at room temperature and taken to the processing laboratory within 4 hours of 192 being drawn. Aliquoted serum samples were frozen at -80°Celcius until assayed. 193 Assays were conducted as previously described [11]. Sera were heat 194 inactivated, tested for nonspecific agglutinins, and adsorbed as needed. Sera were 195 serially diluted 2-fold and incubated with 4 hemagglutination units per 25 µL of virus 196 with erythrocytes for quantification of HAI titers. Turkey erythrocytes were used for 197 the testing of A/H1N1 and B influenza viruses, Guinea pig erythrocytes with 20 mM 198 oseltamivir were used for the testing of A/H3N2 viruses. HAI titer was defined as the 199 reciprocal of the last dilution of serum that completely inhibited hemagglutination. 200 Antibody titers <10 (initial sera dilution) were reported as 5 for analysis. Sera for 201 both vaccine types were tested in HAI assays against egg-grown vaccine strains 202 included in the 2019-20 influenza vaccines (A/Brisbane/02/2018 (H1N1)pdm09, 203 A/Kansas/14/2017 (A/H3N2), B/Colorado/06/2017 (B/Victoria lineage) and 204 B/Phuket/3073/2013 (B/Yamagata lineage), as well as an available cell-grown HAI 205 assay for A/Kansas/14/2017 A/(H3N2). 206 2.4 Statistical analysis 207 Primary outcome measures were post vaccination geometric mean titers

208 (GMT) and geometric mean fold-rise (GMFR) in titers from day 0 to day 28.

209 Secondary outcomes were defined as an HAI titer either 1: ≥40 or 1: ≥110 and

210 seroconversion, defined as a four-fold rise in titer with day 28 post vaccination titer
211 ≥40.

212 Based on previous research comparing seroconversion rates for LAIV4 and 213 ccIIV4, it was determined that a sample size of 200 would be needed to achieve an 214 80% power to detect a significant difference between vaccine types for 215 seroconversion with a moderate effect size of 0.2 [11]. Due to high prevaccination 216 GMT, the primary outcome of this study is reported as GMT and GMFR in titers. A 217 post hoc power calculation of A/H1N1-A/Brisbane day 28 titer outcomes revealed a 218 sample size of 200 had power of 99.8% to detect a difference between vaccine types 219 for day 28 GMT, GMFR in titers and seroconversion. 220 Summary statistics of dichotomous variables were conducted by vaccine 221 group using chi-square/Fisher exact tests for categorial variables and t-tests for 222 continuous variables. Fold-rise was calculated as the ratio of the postvaccination 223 titer to the prevaccination titer. HAI and fold-rise were log<sub>2</sub>-transformed in order to 224 perform t-tests and linear regressions. GMTs, GMFR, and 95% confidence intervals 225 were calculated using the survey means procedure in SAS. Linear regression was 226 used to examine associations between fold-rise controlling for age, pre-vaccination 227 titers, and prior season (2018-19) vaccination status as previously described [14]. All analytical procedures were performed using SAS® 9.4 (Cary, NC). Statistical 228 229 significance of two-sided tests was set at type I error (alpha)=0.05.

230

### 232 3. Results

233	Of 234 persons aged 4 to 21 years assessed for eligibility, 16 were excluded
234	and 218 were randomized: 110 received ccIIV4 and 108 LAIV4. After randomization,
235	20 participants were excluded from the per-protocol analysis: 19 failed to return for
236	post-vaccination specimen collection or were missing paired sera, and one
237	participant in the ccIIV4 group received LAIV4. Per-protocol analysis included 198
238	individuals: 100 received ccIIV4 and 98 received LAIV4 (Figure 1).
239	Patient characteristics were similar for the two vaccine arms (Table 1).
240	Overall, 55% of participants were age 18-21 years, 63% were female, 48% were
241	non-white and 16% were obese. Nearly half of participants were publicly insured,
242	14% were exposed to household smoking and the majority of parents had less than
243	college education. Differences in prior season influenza vaccination (52% vs 47%)
244	were not statistically significant (p=0.48).
245	Pre- and post-vaccination GMTs and mean fold rise in HAI titers are shown by
246	vaccine group in Table 2. Pre-vaccination titers were similar by vaccine group
247	across all antigens; 72%-85% had titers $\geq$ 1:40 and 14%-61% had titers $\geq$ 1:110.
248	After vaccination, GMTs increased significantly against all antigens except among
249	LAIV4 recipients against B/Phuket (Yamagata lineage). All measures of post-
250	vaccination titers, i.e., GMTs, GMFR and proportions with HAI titers $\ge$ 1:40 and $\ge$
251	1:110, were significantly higher among ccIIV4 recipients than LAIV4 recipients
252	across all antigens (all p≤0.02; Table 2). There was no significant difference between
253	GMFR in antibody titer for A/H3N2 tested against cell-grown antigen and A/H3N2
254	tested against egg-grown antigen. Responses to the A/H3N2 antigens in ccIIV4 and
255	LAIV4 recipients are shown in Figure 2.

256	Figures 3a and 3b show patterns of antibody response to vaccination for all
257	antigens. For both ccIIV4 and LAIV4, antibody titers for most participants increased
258	or remained similar to pre-vaccination; greater than two-fold decreased titers were
259	observed in few participants in both vaccine groups. However, patterns of antibody
260	response to vaccination differed significantly by vaccine type across all antigens,
261	including against cell-grown and egg-grown A/H3N2 antigens. For the ccIIV4
262	recipients, a strong "ceiling" effect was observed, with post vaccination titers
263	reaching similar levels across a range of prevaccination titers; whereas antibody
264	titers among LAIV recipients increased more variably from pre- to post vaccination.
265	In regression analyses, lower pre-vaccination titers were associated with greater
266	GMFR in titers in both vaccine groups, although the association was much stronger
267	in the ccIIV4 recipients. Controlling for pre-vaccination HAI titer, prior season (2018-
268	19) vaccination was associated with decreased GMFR against B/Colorado-B/Victoria
269	in ccIIV4 recipients ( $\beta$ =-0.88, p<0.001). With similar adjustments, prior season
270	vaccination was associated with increased GMFR against A/H3N2-A/Kansas egg-
271	grown antigens (ß =0.17, p<0.01) in LAIV4 recipients, but was not independently
272	associated with GMFR against other antigens.
273	

### 274 **4. Discussion**

275	This randomized controlled trial compared antibody responses to cell-grown
276	(ccIIV4) and egg-grown (LAIV4) influenza vaccine in a racially diverse group of
277	children and young adults. Compared to previous work, which used a ccIIV4
278	formulation with three cell-grown antigens and one egg-grown antigen (A/H1N1), this
279	study used a ccIIV4 composed entirely of cell-based antigens. LAIV4 was
280	composed entirely of egg-grown antigens. A/H3N2 strains have become increasingly
281	glycosylated as a result of adaptations required for growth in eggs. These
282	adaptations have led to antigenic differences between vaccine strains and the wild
283	virus [15] and reduced vaccine effectiveness. Thus, cell-grown vaccine strains offer
284	the potential to avoid HA protein mutations that occur in egg-based systems [16].
285	For all measures of HAI response, ccIIV4 elicited significantly larger increases
286	than LAIV4 at 28 days post vaccination. For LAIV4, HAI response was attenuated
287	and seroconversion was infrequent. Our findings are consistent with previous work
288	showing .no HAI marker as a correlate of protection for LAIV4 [17].
289	Lower HAI responses to LAIV compared to IIV have been reported in prior
290	seasons [3, 6, 9, 10]. Our findings with the 2019-20 LAIV4 formulation and fully cell-
291	based ccIIV4 follow a similar pattern. Prior studies have similarly shown a lower HAI
292	response to LAIV in countries where influenza vaccines are routinely administered,
293	although a few earlier studies showed a significant HAI response to LAIV prior to the
294	initiation of routine seasonal vaccination in children [17]. Because of different routes
295	of administration for the two vaccine types, secretory IgA and cellular immune
296	processes stimulated by administration via the nasal route may be a better measure
297	of immune response than HAI for LAIV4 influenza vaccine [6, 10, 18]. Measures of
298	immunoglobulins (IgG and IgA) and cellular immune responses would help delineate

the potential for differences between the vaccine groups not observed in HAI titersalone.

301 When comparing the relationship of pre- to post vaccination titers, with ccIIV4 302 in particular, those with lower pre-vaccination titers had the greatest increase. For 303 both ccIIV4 and LAIV4, participants with high baseline titers remained high. Pre-304 vaccination titer was predictor of post-vaccination titer (positively correlated) and 305 GMFR (negatively correlated). We found similar relative GMFR increases in A/H3N2 306 cell- and egg-grown antigens within vaccine type in the 2019-20 season. 307 A prior study in 2018-19, comparing ccIIV4 with 3 cell-grown and 1 egg-308 grown strains and LAIV4, which incorporated microneutralization measures, found 309 that the GMFR measured using egg-grown A/H3N2 antigen was higher for egg-310 based vaccine than cell-based vaccine recipients [12]. In the current study, GMFR 311 responses to egg- and cell-grown A/H3N2 antigens were similar within vaccine type. 312 Thus, the question of response based on the antigen growth medium is still 313 unresolved. 314 Due to the known effect of baseline titers and prior vaccination history on 315 vaccine response [18], we specifically recruited participants who were not vaccinated 316 in the prior season anticipating that they may have lower titers pre-vaccination and 317 be more likely to mount an HAI response. In post hoc analyses, pre-vaccination titer 318 was a negative predictor of vaccine response for both vaccines, with a greater rise in 319 titer among those with lower pre-vaccination titers. Despite the large proportion of 320 participants unvaccinated in the prior year, only the HAI response to B/Colorado-321 B/Victoria components of both the 2018-19 and 2019-20 vaccines, had an 322 independent association with a smaller GMFR. Prior year vaccination status

323 predicted pre-vaccination titers and fold-rise in titers, vaccination with ccIIV4

324 remaining a stronger predictor of fold-rise after adjusting for prior year vaccination

325 status. Pre-vaccination titers as well as prior year vaccination status should be

326 considered in determination of degree of vaccine response.

- 327 4.1 Strengths and Limitations
- 328 A strength of this study was the relatively large randomized controlled sample.

329 Small sample size within the youngest age group limited power to detect differences

330 by age. Participants were historically highly vaccinated with high pre-vaccination

titers, and repeated vaccination with egg-based vaccines may affect antibody

332 responses to cell-based antigens. Overall, immune responses may not predict

- 333 vaccine effectiveness, especially for LAIV for which better correlates of protection
- are needed.
- 335 4.2 Conclusions

336 In this racially diverse group of children and young adults, half of whom were

337 unvaccinated in the prior season, all measures of HAI titers were higher among

338 ccIIV4 recipients than LAIV recipients. Even among vaccine recipients with high pre-

339 vaccination titers, HAI titers remained high post vaccination. Responses to ccIIV4

- and LAIV4 as measured by GMFR were consistent against egg- and cell-grown
- 341 antigens. Future studies are needed to examine the immunoglobulin and cellular

immune responses in the 2019-20 season to ccIIV4 and LAIV4.

- 343 Funding and support
- 344 This work was supported by the Centers for Disease Control and Prevention
- 345 (CDC) [5U01IP001035] and by National Institutes of Health (NIH) [UL1TR001857],

346 [KL2 TR001856], and/or [TL1 TR001858]. This work represents the views of the

authors and not the CDC or NIH.

348	Pennsylvania Statewide Immunization Information System (PA-SIIS) vaccine
349	registry was used to verify vaccination status. These data were supplied in part by
350	the Bureau of Health Statistics & Registries, Pennsylvania Department of Health,
351	Harrisburg, Pennsylvania. The Pennsylvania Department of Health specifically
352	disclaims responsibility for any analyses, interpretations, or conclusions.
353	REDCap and the Department of Biomedical Informatics grant support (Clinical
354	and Translational Sciences Institute at the University of Pittsburgh Grant Number
355	UL1-TR-001857). Study data were collected and managed using REDCap electronic
356	data capture tools hosted at the University of Pittsburgh.
357	Conflict of Interest: RKZ has received funding by Sanofi for an unrelated study.
358	MPN has research funding from Merck & Co., Inc. for an unrelated study. JMM has
359	received funding from Merck, Sharp and Dohme for an unrelated study.

#### 361 **5. References Cited**

- 362 [1] Centers for Disease Control. Disease Burden of Influenza.
- 363 <u>https://www.cdc.gov/flu/about/burden/index.html</u>. Accessed June 30, 2021.
- 364 [2] Grohskopf LA, Alyanak E, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and
- 365 Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee
- 366 on Immunization Practices United States, 2019-20 Influenza Season. MMWR
- 367 Recommendations and reports : Morbidity and mortality weekly report Recommendations
- 368 and reports. 2019;68:1-21. 10.15585/mmwr.rr6803a1
- 369 [3] King JP, McLean HQ, Meece JK, Levine MZ, Spencer SM, Flannery B, et al. Vaccine
- 370 failure and serologic response to live attenuated and inactivated influenza vaccines in
- 371 children during the 2013–2014 season. Vaccine. 2018;36. 10.1016/j.vaccine.2018.01.016
- 372 [4] Nuñez IA, Carlock MA, Allen JD, Owino SO, Moehling KK, Nowalk P, et al. Impact of age
- 373 and pre-existing influenza immune responses in humans receiving split inactivated influenza
- 374 vaccine on the induction of the breadth of antibodies to influenza A strains. PLoS ONE.
- 375 2017;12. 10.1371/journal.pone.0185666
- 376 [5] Zhong W, Tobler S, Roayaei J. Live attenuated or inactivated influenza vaccines and
- 377 medical encounters for respiratory illnesses among US military personnel. JAMA Journal of
- 378 the American Medical Association. 2009;301. 10.1001/jama.2009.265
- [6] Hoft DF, Lottenbach KR, Blazevic A, Turan A, Blevins TP, Pacatte TP, et al.
- 380 Comparisons of the humoral and cellular immune responses induced by live attenuated
- 381 influenza vaccine and inactivated influenza vaccine in adults. Clinical and Vaccine
- 382 Immunology. 2017;24:e00414-16. 10.1128/CVI.00414-16
- 383 [7] Ambrose CS, Wu X, Knuf M, Wutzler P. The efficacy of intranasal live attenuated
- influenza vaccine in children 2 through 17 years of age: A meta-analysis of 8 randomized
- 385 controlled studies. Vaccine. 2012;30:886-92. 10.1016/j.vaccine.2011.11.104
- 386 [8] Barr IG, Donis RO, Katz JM, McCauley JW, Odagiri T, Trusheim H, et al. Cell culture-
- 387 derived influenza vaccines in the severe 2017-2018 epidemic season: a step towards

- improved influenza vaccine effectiveness. NPJ Vaccines. 2018;3:1-5. 10.1038/s41541-018-
- 389 0079-z
- 390 [9] Martin JM, Avula R, Nowalk MP, Lin CJ, Horne WT, Chandran UR, et al. Inflammatory
- 391 mediator expression associated with antibody response induced by live attenuated vs
- 392 inactivated influenza virus vaccine in children. Open Forum Infectious Diseases. 2018;5:1-
- 393 10. 10.1093/ofid/ofy277
- [10] Manenti A, Tete SM, Mohn KGI, Jul-Larsen Å, Gianchecchi E, Montomoli E, et al.
- 395 Comparative analysis of influenza A(H3N2) virus hemagglutinin specific IgG subclass and
- 396 IgA responses in children and adults after influenza vaccination. Vaccine. 2017;35:191-8.
- 397 10.1016/j.vaccine.2016.10.024
- 398 [11] Jhaveri R. Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of
- 399 Future Results? Clin Ther. 2018;40:1246-54. 10.1016/j.clinthera.2018.07.003
- 400 [12] Moehling KK, Zimmerman RK, Nowalk MP, Jeng Lin C, Martin JM, Alcorn JF, et al. A
- 401 randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based
- 402 quadrivalent inactivated influenza vaccine in children. Vaccine. 2020;38:5171-7.
- 403 10.1016/j.vaccine.2020.06.023
- 404 [13] Centers for Disease Control. Flu Vaccination Coverage, United States, 2019–20
- 405 Influenza Season. <u>https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm</u>.
- 406 Accessed May 25, 2021.
- 407 [14] Hinojosa M, Shepard SS, Chung JR, King JP, McLean HQ, Flannery B, et al. Impact of
- 408 Immune Priming, Vaccination, and Infection on Influenza A(H3N2) Antibody Landscapes in
- 409 Children. The Journal of Infectious Diseases. 2021;224:469-80. 10.1093/infdis/jiaa665
- 410 [15] Zost SJ, Parkhouse K, Gumina ME, Kim K, Perez SD, Wilson PC, et al. Contemporary
- 411 H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by
- 412 egg-adapted vaccine strains. Proceedings of the National Academy of Sciences of the
- 413 United States of America. 2017;114. 10.1073/pnas.1712377114
- 414 [16] Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New Technologies for Influenza
- 415 Vaccines. Microorganisms. 2020;8:45-58. 10.3390/microorganisms8111745

- 416 [17] Mohn KG, Smith I, Sjursen H, Cox RJ. Immune responses after live attenuated influenza
- 417 vaccination. Hum Vaccin Immunother. 2018;14:571-8. 10.1080/21645515.2017.1377376
- 418 [18] Brickley EB, Wright PF, Khalenkov A, Neuzil KM, Ortiz JR, Rudenko L, et al. The Effect
- 419 of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II,
- 420 Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in
- 421 Bangladeshi Children. Clinical Infectious Diseases. 2019;69:786-94. 10.1093/cid/ciy1004

Table 1. Demographics by 2019-20 influenza vaccine type received.

Variable	Overall	ccllV4	LAIV4	p-value*
	N=198	N=100	N=98	
Age (years), median (Q1, Q3)	18.3 (14.6-20.5)	18.1 (14.7-20.4)	18.4 (14.3-20.7)	0.61
Age				0.75
4-11 years	31 (15.7)	17 (17.0)	14 (14.3)	
12-17 years	59 (27.8)	31 (31.0)	28 (28.6)	
18-21 years	108 (54.5)	52 (52.0)	56 (57.1)	
Female (ref.=male), n (%)	124 (62.6)	64 (64.0)	60 (61.2)	0.69
Non-white race (ref.=white), n (%)	95 (48.0)	43 (43.0)	52 (53.1)	0.16
Non-Hispanic (ref.=Hispanic), n (%)	184 (92.9)	95 (95.0)	89 (90.8)	0.11
Parental education < some college	122 (61.6)	62 (62.0)	60 (61.2)	0.99
(ref.=≥college), n (%)				
Public health insurance (ref.=other	95 (48.0)	48 (48.0)	47 (48.0)	0.87
insurance), n (%)				
Exposed to household smoking	28 (14.1)	15 (15.0)	13 (13.3)	0.68
(ref.=no smoke exposure), n (%)				
Obese (ref.=non-obese), n (%)	31 (15.7)	13 (13.0)	18 (18.4)	0.28

2018 influenza vaccine status	
-------------------------------	--

Vaccinated	98 (49.5)	52 (52.0)	46 (46.9)
Not vaccinated/no record	100 (50.5)	48 (48.0)	52 (53.1)

\*Wilcoxon ranked sum for continuous variables, chi-square/Fisher's Exact for categorical variables.

Nonwhite race = AIAN, Asian, Black, NHPI, multi-race.

Other insurance = Private, non-insured, combined private and public insurance.

Obesity defined as  $\ge 95^{\text{th}}$  percentile for BMI if <20 years or BMI $\ge 30$  if  $\ge 20$  years.

- ccIIV4 = cell-based quadrivalent inactivated influenza vaccine
- LAIV4 = egg-based quadrivalent live-attenuated influenza vaccine

0.48

# Table 2. Pre- and post vaccination hemagglutination inhibition (HAI) assay titer

# responses by vaccine type

	ccIIV4 LAIV4		p-value*
	N=100	N=98	
A/H1N1-A/Brisbane Egg Grown Virus			
Day 0 HAI GMT (95% CI)	90 (73-111)	94 (77-116)	0.79
Day 28 HAI GMT (95% CI)	269 (228-317) <sup>†</sup>	108 (89-132) <sup>†</sup>	<0.001
Mean fold-rise in HAI titer (95% CI)	3.0 (2.5-3.6)	1.1 (1.0-1.3)	<0.001
Seroconversion ≥1:40, n (%)	33 (33.0)	5 (5.1)	<0.001
Day 0 HAI titer ≥1:40, n (%)	83 (83.0)	79 (80.6)	0.66
Day 28 HAI titer ≥1:40, n (%)	96 (96.0)	85 (86.7)	0.02
Day 0 HAI titer ≥1:110, n (%)	61 (61.0)	54 (55.1)	0.40
Day 28 HAI titer ≥1:110, n (%)	93 (93.0)	58 (59.2)	<0.001
A/H3N2-A/Kansas Egg Grown Virus			
Day 0 HAI GMT (95% CI)	78 (66-95)	75 (64-89)	0.79
Day 28 HAI GMT (95% CI)	205 (178-237) <sup>†</sup>	96 (83-112) <sup>†</sup>	<0.001
Mean fold-rise in HAI titer (95% CI)	2.6 (2.2-3.1)	1.3 (1.1-1.4)	<0.001
Seroconversion ≥1:40, n (%)	44 (44.0)	11 (11.2)	<0.001
Day 0 HAI titer ≥1:40, n (%)	85 (85.0)	83 (84.0)	0.95
Day 28 HAI titer ≥1:40, n (%)	99 (99.0)	90 (91.8)	0.02
Day 0 HAI titer ≥1:110, n (%)	41 (41.0)	34 (34.7)	0.36
Day 28 HAI titer ≥1:110, n (%)	77 (77.0)	41 (41.8)	<0.001
A/H3N2-A/Kansas Cell Grown Virus			

Day 0 HAI GMT (95% CI)	46 (38-55)	50 (43-58)	0.56	
Day 28 HAI GMT (95% CI)	136 (113-165) <sup>†</sup>	63 (58-74) <sup>†</sup>	<0.001	
Mean fold-rise in HAI titer (95% CI)	3.0 (2.5-3.6)	1.3 (1.1-1.4)	<0.001	
Seroconversion ≥1:40, n (%)	47 (47.0)	8 (8.2)	<0.001	
Day 0 HAI titer ≥1:40, n (%)	72 (72.0)	81 (82.7)	0.07	
Day 28 HAI titer ≥1:40, n (%)	93 (93.0)	80 (81.6)	0.02	
Day 0 HAI titer ≥1:110, n (%)	24 (24.0)	14 (14.3)	0.08	
Day 28 HAI titer ≥1:110, n (%)	65 (65.0)	26 (26.5)	<0.001	
B/Victoria-B/Colorado Egg Grown Vir	us			
Day 0 HAI GMT (95% CI)	65 (53-79)	65 (53-81)	0.95	
Day 28 HAI GMT (95% CI)	158 (134-186) <sup>†</sup>	78 (64-94) <sup>†</sup>	<0.001	
Mean fold-rise in HAI titer (95% CI)	2.4 (2.0-2.9)	1.2 (1.0-1.4)	<0.001	
Seroconversion ≥1:40, n (%)	28 (28.0)	9 (9.2)	<0.001	
Day 0 HAI titer ≥1:40, n (%)	75 (75.0)	72 (73.5)	0.81	
Day 28 HAI titer ≥1:40, n (%)	96 (96.0)	79 (80.6)	<0.001	
Day 0 HAI titer ≥1:110, n (%)	34 (34.0)	34 (34.7)	0.91	
Day 28 HAI titer ≥1:110, n (%)	71 (71.0)	36 (36.7)	<0.001	
B/Yamagata-B/Phuket Egg Grown Virus				
Day 0 HAI GMT (95% CI)	89 (74-107)	101 (83-122)	0.44	
Day 28 HAI GMT (95% CI)	215 (191-241) <sup>†</sup>	107 (90-128)	<0.001	
Mean fold-rise in HAI titer (95% CI)	2.4 (2.0-2.9)	1.1 (1.0-1.2)	<0.001	
Seroconversion ≥1:40, n (%)	29 (29.0)	4 (4.1)	<0.001	
Day 0 HAI titer ≥1:40, n (%)	86 (86.0)	84 (85.7)	0.95	

Day 28 HAI titer ≥1:40, n (%)	100 (100)	89 (90.8)	0.002
Day 0 HAI titer ≥1:110, n (%)	51 (51.0)	57 (58.2)	0.31
Day 28 HAI titer ≥1:110, n (%)	84 (84.0)	57 (58.2)	<0.001

ccIIV4 = cell-based quadrivalent inactivated influenza vaccine; LAIV4 = egg-based quadrivalent live-attenuated influenza vaccine; GMT = geometric mean titer; CI = confidence interval; Seroconversion = HAI titer ratio of day 28/day 0  $\geq$ 4 and HAI titer at day 28  $\geq$ 40. Primary outcome was mean fold-rise in HAI titer.

\*t-test was used to compare log titers by vaccine type; Chi-square test was used to compare rates.

<sup>†</sup>p<0.05 for paired t-test comparison to Day 0 GMT.

# Figure 1: CONSORT 2010 Flow Diagram




Figure 2. Pre- and post-vaccination GMT hemagglutination inhibition (HAI) assay titers by vaccine type for A/H3N2-A/Kansas egg and cell grown viruses. Data are day 0 (black) and day 28 (gray) with 95% confidence Intervals (CI), GMFR with 95% CI is shown horizontally above bars. Within each vaccine type, egg grown antigens were higher than cell grown at days 0 and 28 (p<0.001), but the GMFR did not differ between egg and cell. Between vaccine types, HAI titers at day 28 and GMFR were lower for LAIV4 for each respective antigen (p<0.001).</p>

8

Figure 3a. Hemagglutination inhibition (HAI) titers for influenza A antigens on day 0
and day 28 for ccIIV4 (left) and LAIV4 (right). Identical day 0 and day 28 titers fall on
the dotted line. Data points above the line represent an increase in HAI at day 28
and data points below represent a decrease.

Figure 3b. Hemagglutination inhibition (HAI) titers for influenza B antigens on day 0

and day 28 for ccIIV4 (left) and LAIV4 (right). Identical day 0 and day 28 titers fall on
the dotted line. Data points above the line represent an increase in HAI at day 28
and data points below represent a decrease.




Figure 2. Pre- and post-vaccination GMT hemagglutination inhibition (HAI) assay titers by vaccine type for A/H3N2-A/Kansas egg and cell grown viruses. Data are day 0 (white) and day 28 (gray) with 95% confidence Intervals (CI), GMFR with 95% CI is shown horizontally above bars. Within each vaccine type, egg grown antigens were higher than cell grown at days 0 and 28 (p<0.001), but the GMFR did not differ between egg and cell. Between vaccine types, HAI titers at day 28 and GMFR were lower for LAIV4 for each respective antigen (p<0.0001).

